Abstract

Objective: To review the management of traditional and nontraditional CVD cardiovascular disease risk factors in rheumatoid arthritis (RA). Methods: Literature review of the management of CVD risk in RA. Results: Because of the increased risk of CVD events and CVD mortality among RA patients, aggressive management of CVD risk is essential. Providers should follow national guidelines for the management of traditional CVD risk factors, including dyslipidemia, hypertension, and diabetes mellitus. Similar efforts are needed in counseling on lifestyle modifications, including smoking cessation, regular exercise, and maintaining a healthy body weight. Because higher RA disease activity is also linked with CVD risk, aggressive treatment of RA to a target of low disease activity or remission is critical. Furthermore, the selection of potentially “cardioprotective” agents such as methotrexate and tumor necrosis factor inhibitors, while limiting use of nonsteroidal anti-inflammatory drugs and glucocorticoids, are strategies that could be employed by rheumatologists to help mitigate CVD risk in their patients with RA. Conclusion: Routine assessment of CVD risk, management of traditional CVD risk factors, counseling on healthy lifestyle habits, and aggressive treatment of RA are essential to minimize CVD risk in this population.

Original languageEnglish (US)
Pages (from-to)79-89
Number of pages11
JournalJournal of Clinical Outcomes Management
Volume26
Issue number2
StatePublished - Mar 2019

Fingerprint

Rheumatoid Arthritis
Cardiovascular Diseases
Risk Management
Counseling
Cardiotonic Agents
Smoking Cessation
Dyslipidemias
Methotrexate
Glucocorticoids
Habits
Life Style
Diabetes Mellitus
Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha
Body Weight
Guidelines
Exercise
Hypertension
Mortality
Therapeutics

Keywords

  • Cardiovascular disease
  • Cardiovascular risk assessment
  • Cardiovascular risk management
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Health Policy

Cite this

Management of cardiovascular disease risk in rheumatoid arthritis. / Johnson, Tate M.; Mikuls, Ted R.; England, Bryant R.

In: Journal of Clinical Outcomes Management, Vol. 26, No. 2, 03.2019, p. 79-89.

Research output: Contribution to journalArticle

@article{e5df1f3793f54d589cc22058316d7a36,
title = "Management of cardiovascular disease risk in rheumatoid arthritis",
abstract = "Objective: To review the management of traditional and nontraditional CVD cardiovascular disease risk factors in rheumatoid arthritis (RA). Methods: Literature review of the management of CVD risk in RA. Results: Because of the increased risk of CVD events and CVD mortality among RA patients, aggressive management of CVD risk is essential. Providers should follow national guidelines for the management of traditional CVD risk factors, including dyslipidemia, hypertension, and diabetes mellitus. Similar efforts are needed in counseling on lifestyle modifications, including smoking cessation, regular exercise, and maintaining a healthy body weight. Because higher RA disease activity is also linked with CVD risk, aggressive treatment of RA to a target of low disease activity or remission is critical. Furthermore, the selection of potentially “cardioprotective” agents such as methotrexate and tumor necrosis factor inhibitors, while limiting use of nonsteroidal anti-inflammatory drugs and glucocorticoids, are strategies that could be employed by rheumatologists to help mitigate CVD risk in their patients with RA. Conclusion: Routine assessment of CVD risk, management of traditional CVD risk factors, counseling on healthy lifestyle habits, and aggressive treatment of RA are essential to minimize CVD risk in this population.",
keywords = "Cardiovascular disease, Cardiovascular risk assessment, Cardiovascular risk management, Rheumatoid arthritis",
author = "Johnson, {Tate M.} and Mikuls, {Ted R.} and England, {Bryant R.}",
year = "2019",
month = "3",
language = "English (US)",
volume = "26",
pages = "79--89",
journal = "Journal of Clinical Outcomes Management",
issn = "1079-6533",
publisher = "Turner White Communications Inc.",
number = "2",

}

TY - JOUR

T1 - Management of cardiovascular disease risk in rheumatoid arthritis

AU - Johnson, Tate M.

AU - Mikuls, Ted R.

AU - England, Bryant R.

PY - 2019/3

Y1 - 2019/3

N2 - Objective: To review the management of traditional and nontraditional CVD cardiovascular disease risk factors in rheumatoid arthritis (RA). Methods: Literature review of the management of CVD risk in RA. Results: Because of the increased risk of CVD events and CVD mortality among RA patients, aggressive management of CVD risk is essential. Providers should follow national guidelines for the management of traditional CVD risk factors, including dyslipidemia, hypertension, and diabetes mellitus. Similar efforts are needed in counseling on lifestyle modifications, including smoking cessation, regular exercise, and maintaining a healthy body weight. Because higher RA disease activity is also linked with CVD risk, aggressive treatment of RA to a target of low disease activity or remission is critical. Furthermore, the selection of potentially “cardioprotective” agents such as methotrexate and tumor necrosis factor inhibitors, while limiting use of nonsteroidal anti-inflammatory drugs and glucocorticoids, are strategies that could be employed by rheumatologists to help mitigate CVD risk in their patients with RA. Conclusion: Routine assessment of CVD risk, management of traditional CVD risk factors, counseling on healthy lifestyle habits, and aggressive treatment of RA are essential to minimize CVD risk in this population.

AB - Objective: To review the management of traditional and nontraditional CVD cardiovascular disease risk factors in rheumatoid arthritis (RA). Methods: Literature review of the management of CVD risk in RA. Results: Because of the increased risk of CVD events and CVD mortality among RA patients, aggressive management of CVD risk is essential. Providers should follow national guidelines for the management of traditional CVD risk factors, including dyslipidemia, hypertension, and diabetes mellitus. Similar efforts are needed in counseling on lifestyle modifications, including smoking cessation, regular exercise, and maintaining a healthy body weight. Because higher RA disease activity is also linked with CVD risk, aggressive treatment of RA to a target of low disease activity or remission is critical. Furthermore, the selection of potentially “cardioprotective” agents such as methotrexate and tumor necrosis factor inhibitors, while limiting use of nonsteroidal anti-inflammatory drugs and glucocorticoids, are strategies that could be employed by rheumatologists to help mitigate CVD risk in their patients with RA. Conclusion: Routine assessment of CVD risk, management of traditional CVD risk factors, counseling on healthy lifestyle habits, and aggressive treatment of RA are essential to minimize CVD risk in this population.

KW - Cardiovascular disease

KW - Cardiovascular risk assessment

KW - Cardiovascular risk management

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=85066931875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066931875&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85066931875

VL - 26

SP - 79

EP - 89

JO - Journal of Clinical Outcomes Management

JF - Journal of Clinical Outcomes Management

SN - 1079-6533

IS - 2

ER -